IL22 and Alzheimer disease: This study found that Aptamin C downregulates the production of IL-22 and the expression of its receptor by stimulating GDNF production in AD skin lesions, suggesting that Aptamin C, with anti-itching and anti-inflammatory activities, has potential as a therapeutic agent in the treatment of patients with AD.